LLY

785.76

-1.21%↓

JNJ

152.76

+0.26%↑

ABBV

186.41

-0.43%↓

NVO

68.78

+2.32%↑

UNH

307.81

+1.17%↑

LLY

785.76

-1.21%↓

JNJ

152.76

+0.26%↑

ABBV

186.41

-0.43%↓

NVO

68.78

+2.32%↑

UNH

307.81

+1.17%↑

LLY

785.76

-1.21%↓

JNJ

152.76

+0.26%↑

ABBV

186.41

-0.43%↓

NVO

68.78

+2.32%↑

UNH

307.81

+1.17%↑

LLY

785.76

-1.21%↓

JNJ

152.76

+0.26%↑

ABBV

186.41

-0.43%↓

NVO

68.78

+2.32%↑

UNH

307.81

+1.17%↑

LLY

785.76

-1.21%↓

JNJ

152.76

+0.26%↑

ABBV

186.41

-0.43%↓

NVO

68.78

+2.32%↑

UNH

307.81

+1.17%↑

Search

Insmed

Avatud

SektorTervishoid

101.65 -2.73

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

101.1

Max

104.69

Põhinäitajad

By Trading Economics

Sissetulek

-21M

-257M

Müük

-12M

93M

Aktsiakasum

-1.32

Kasumimarginaal

-276.422

Töötajad

1,271

EBITDA

-38M

-248M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+5.57% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. aug 2025

Turustatistika

By TradingEconomics

Turukapital

8.4B

20B

Eelmine avamishind

104.38

Eelmine sulgemishind

101.65

Uudiste sentiment

By Acuity

14%

86%

20 / 380 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Insmed Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. juuni 2025, 12:53 UTC

Suurimad hinnamuutused turgudel

Insmed Shares Rise on Positive Results From Study of Treatment for High Blood Pressure in Lungs

Võrdlus sarnastega

Hinnamuutus

Insmed Prognoos

Hinnasiht

By TipRanks

5.57% tõus

12 kuu keskmine prognoos

Keskmine 110.69 USD  5.57%

Kõrge 124 USD

Madal 90 USD

Põhineb 17 Wall Streeti analüütiku instrumendi Insmed 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

17 ratings

17

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

N/A / 69.2Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Very Strong Bearish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

20 / 380 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Insmed

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.